Enoxaparin (CAS 91449-79-5)/ Anticoagulant

Enoxaparin (CAS 91449-79-5) is a high-purity pharmaceutical API classified as a potent low-molecular-weight heparin (LMWH), derived from unfractionated heparin through controlled depolymerization. It features a heterogeneous polysaccharide structure with specific affinity for antithrombin III, enhancing its ability to inhibit factor Xa—delivering targeted anticoagulant effects with a reduced risk of bleeding compared to unfractionated heparin. This API presents as a white to off-white powder with excellent water solubility, facilitating formulation into injectable dosage forms.

It caters to the core needs of cardiovascular drug manufacturers, anticoagulant therapy developers, and clinical supply chains. Widely applied in preventing and treating venous thromboembolism (VTE), pulmonary embolism (PE), and acute coronary syndromes (ACS), it aligns with demand for safe, predictable anticoagulant therapies. Produced under strict GMP standards, each batch undergoes rigorous molecular weight distribution, anti-Xa activity, and purity testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing reliable anticoagulant solutions, this Enoxaparin API serves as a critical raw material for advancing thromboprophylaxis and anticoagulant medication development.